Condition: Rheumatoid Arthritis (RA) · Sponsor: Kali Therapeutics, Inc.
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.
This description comes directly from the study's public registry record.
Trial Information · 1-858-888-3080 · clinical@kalitherapeutics.com
Always discuss trial participation with your own doctor first.
| Kali Therapeutics Trial Site | Bayswater, Victoria, Australia | Recruiting |
| Kali Therapeutics Trial Site | Auckland, NZ, New Zealand | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07564154